CAPHRA calls for regulated access to e-cigarettes in Australia

Dec.16.2022
CAPHRA calls for regulated access to e-cigarettes in Australia
CAPHRA submits consultation document to TGA for access to legal electronic cigarettes and nicotine in Australia.

According to a submission by the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA), just over 1% of people capable of writing nicotine scripts actually do so. Less than one-third of authorized prescribers are publicly available for adult smokers seeking to switch to nicotine e-cigarettes due to Australia's failed medicalized model.


CAPHRA has submitted a consultation paper to the Therapeutic Goods Administration (TGA) in Australia, discussing various options for legally obtaining electronic cigarettes and nicotine.


Australia remains the only Western democracy that requires a prescription for nicotine electronic cigarettes. The public consultation period regarding the proposed reform on the regulation of nicotine e-cigarette products in Australia began on November 30th and ended on January 16th, 2023.


Over the past decade, smoking rates in Australia have remained stable, particularly among vulnerable and disadvantaged communities. Nancy Loucas, the executive coordinator of CAPHRA, stated that "electronic cigarettes are one of the most effective methods for smokers worldwide to quit smoking, and access to them at retail outlets should have been restricted long ago.


CAPHRA stated that several countries, including the European Union, the United Kingdom, New Zealand, and Canada, are currently utilizing electronic cigarettes and reduced harm products to influence the rapid decline in smoking prevalence in these countries.


Ms. Lucas stated that the most deadly product to the public, combustible tobacco, is still readily available at any ordinary retailer, which is a mockery of public health.


Australia needs to determine whether their nicotine policy decisions are based on science, evidence, and facts to promote and maintain the health of their population, or if they choose money over health regarding tobacco consumption taxes and other possible funding they may receive due to their severe policy, which has proven to be a failure, according to CAPHRA.


Australian politicians and officials may not like to hear it, but if they want to see success, they need only cross the Tasman Sea. New Zealand has adopted an active harm reduction approach towards tobacco, and in the past decade, with the implementation of the Smokefree 2025 goal, their overall smoking rate has halved. Now they aim to achieve a regular smoking rate of only 5% or less. "Ms Loucas said.


Similarly, CAPHRA wrote that if youth access is truly a concern for Australian policymakers, the only solution is proper regulation and imposing strict fines and license revocations for non-compliant retailers. New Zealand's 2020 e-cigarette legislation and subsequent regulations achieved this.


According to Ms. Loucas, New Zealand has an effective consumer framework. In fact, in the past year alone, over 150,000 New Zealanders have switched from deadly combustible products to safer nicotine alternatives.


The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) believes that a regulated consumer market will enable Australia to have necessary control over the quality and quantity of products sold by community retailers. It also allows for products to be restricted to adults only – similar to alcohol and combustible cigarettes.


The report points out that there is currently a prevalence of unregulated black market products in Australia, with no regulatory control over their content or access for individuals under the age of 18.


We, on behalf of our nine member organizations, have submitted a letter of objection to the consultation document advocating for the 'gateway theory.' Despite the document's claim of evidence that electronic cigarettes lead to youth smoking, the gateway theory has been both confirmed and questioned by numerous international research institutions. Ms. Loucas stated that electronic cigarettes are an exit from smoking, not an entrance.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives